Exploring breakthrough treatments including Iptacopan for C3 glomerulonephritis (C3 GN), C3G, and PNH - Highlights from ASN Kidney Week 2024
Stay informed about groundbreaking developments in complement-targeted therapeutics, including Iptacopan and other innovative treatments. Our expert analysis covers the latest clinical trials and research in complement cascade modulation - essential for treating rare diseases like C3 glomerulonephritis (C3 GN), C3 glomerulopathy (C3G), paroxysmal nocturnal hemoglobinuria (PNH), and other complement-mediated disorders.
At UKidney's Complement Corner, we provide comprehensive coverage of factor B inhibitors, complement pathway therapeutics, and emerging treatment approaches for C3 glomerulonephritis (C3 GN). Our platform delivers valuable insights for nephrologists, hematologists, researchers, and patients seeking the latest advances in complement-targeted therapies and clinical outcomes.
Join our community to receive expert updates on complement inhibition strategies, real-world evidence, and transformative therapies reshaping the treatment landscape for complement-mediated diseases, including C3 glomerulonephritis (C3 GN). Subscribe now for exclusive access to our latest analyses and clinical insights.
Loading presentation 1...
APPEAR C3G Trial
Clinical trial findings and outcomes summary.
A Pivotal Phase 3 Study of Iptacopan in C3 Glomerulopathy
Loading presentation 1...
Latest Advances in Complement Biology and Clinical Applications
Thanks for watching!
We'd love your feedback on the Complement Biology presentation.
Take Quick SurveyLoading presentation 2...
Exploring Advanced Complement Biology and Therapeutic Innovations
Thanks for watching!
We'd love your feedback on the Spotlight on Complement Part 2 presentation.
Take Quick SurveyLoading presentation 4...
Advanced Therapeutic Approaches and Patient Management Strategies
Thanks for watching!
We'd love your feedback on the Clinical Applications presentation.
Take Quick SurveyLeading experts in nephrology and complement-mediated diseases
University of Calgary
MD, MBT, FRCPC
Nephrologist and Clinical Associate Professor
Medical Director of Glomerulonephritis
Dr. Louis Girard joined the Division of Nephrology at the University of Calgary in July of 2010. He focuses on clinical immunology and infectious diseases in chronic kidney disease patients.
Dr. Louis Girard joined the Division of Nephrology at the University of Calgary in July of 2010. He is a Nephrologist and a Clinical Professor of Medicine.
Within the Division of Nephrology, Dr. Girard focuses on clinical immunology, genetics and infectious diseases in patients with kidney disease. He is the medical director of the Glomerulonephritis Clinic and Apheresis. He has developed several specialty clinics for the treatment of rare diseases, including clinics for the treatment of complement mediated disease, Tuberous Sclerosis and Autosomal Dominant Polycystic Kidney Disease. His work in this area was recognized with the Dr. John Conly award for innovation.
Recently, he became the program director of the newly created GN Fellowship program, which has its first trainee, who started training July 2022. Additionally, he is the co-chair of the Glomerulonephritis and Diabetic Kidney Disease sub-committees of the Medicine Strategic Clinical Network for Alberta Health. Dr. Girard is the co-chair of CAN-PKD.
He is heavily involved in clinical trials. He has several peer-reviewed publications including a co-authored publication in the New England Journal of Medicine. Furthermore, he is a member of CAN-VASC and is a co-author on the most recent Canadian ANCA Vasculitis guidelines.
Dr. Girard is also a member of the Canadian Apheresis Group as well as the Executive Planning Group. As part of his role within CAG, Dr. Girard also serves on the TMA/TTP working groups. Additionally, he is a committee member on the authorship group that wrote the Canadian consensus recommendations on ADPKD and the update to that document.
Dr. Girard has a strong commitment to education and has won numerous awards for his teaching contributions at all levels of medical training.
McGill University Health Center
MSc, MDCM, FRCPC
Associate Professor, Division of Nephrology
MGH Site Director for Nephrology
Dr. Samanta is an Associate Professor at McGill University, with expertise in Chronic Disease Epidemiology from Yale University and specialized training in Glomerulonephritis from the University of Toronto.
Dr. Samanta is an Associate Professor at McGill University; she obtained her Masters degree at Yale University in Chronic Disease Epidemiology and then completed a clinical fellowship in Glomerulonephritis at the University of Toronto.
After joining McGill, Dr Samanta started the MUHC GlomeruloNephritis Clinic, and serves as the nephrology liaison for the monthly joint Rheum-Nephro Lupus clinic. She chairs the monthly McGill NephroPathology Rounds, and has given various talks on the national stage on the management of glomerular disease and lupus.
Dr Samanta is involved in various multinational clinical trials in glomerular diseases and has worked in conjunction with NephCure, to organize and chair the first Montreal-based patient conference to heighten patients' understanding of glomerular disease and treatment opportunities.
Dr. Samanta is the Site Director for Nephrology at the Montreal General Hospital, and also serves on the Canadian Society of Nephrology (CSN) Board of Directors as the Director at Large for Quebec.
Please complete this brief assessment before viewing the content
Please complete this brief assessment to finish the module